Jupiter Neurosciences Receivables 2023-2025 | JUNS

Jupiter Neurosciences receivables from 2023 to 2025. Receivables can be defined as the total amount of collectibles for a company

Jupiter Neurosciences Receivables 2023-2025 | JUNS

Jupiter Neurosciences receivables from 2023 to 2025. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$75.3B
Zoetis (ZTS)$68.1B
Takeda Pharmaceutical (TAK)$46.9B
Daiichi Sankyo, - (DSNKY)$43.1B
BeOne Medicines - (ONC)$29.6B
Sandoz Group AG (SDZNY)$25B
Summit Therapeutics (SMMT)$18.1B
Merck (MKKGY)$16.5B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.2B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.2B
Stevanato Group S.p.A (STVN)$7.8B
Corcept Therapeutics (CORT)$7.6B
Madrigal Pharmaceuticals (MDGL)$6.9B
Grifols, S.A (GRFS)$6.7B
Ionis Pharmaceuticals (IONS)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.3B
Soleno Therapeutics (SLNO)$4.2B
Hypermarcas (HYPMY)$3.2B
Crinetics Pharmaceuticals (CRNX)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$2B
BioCryst Pharmaceuticals (BCRX)$1.8B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.7B